Tesamorelin prescription requirements: what you actually need

Last updated 2026-07-25

Is tesamorelin available without a prescription?

No. Tesamorelin is not available over the counter anywhere in the United States. The FDA-approved version, Egrifta (and the newer needle-free-reconstitution formulation Egrifta SV), is a prescription drug, full stop ^[1][2]. That's different from a lot of the peptide market, where research-chemical sellers ship vials with no prescription and a "not for human consumption" disclaimer. Tesamorelin itself, as the approved branded product, doesn't move through that channel legally. If you see it sold that way, you're looking at a compounded or gray-market version, not the approved drug, and the legal and quality picture changes completely. Compounded tesamorelin exists because tesamorelin base is on FDA's list of bulk drug substances that can be used under section 503A compounding, and it also appears on the 503B bulks list for outsourcing facilities . Compounded versions still require a prescription. They're just not the FDA-reviewed, batch-tested Egrifta product, and they don't carry the same manufacturing oversight.

What is tesamorelin actually FDA-approved for?

Tesamorelin is approved for one specific thing: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy ^[1][2]. That's it. It is not approved for general weight loss, for bodybuilding, for anti-aging, or for growth hormone deficiency outside that population. The approval rests on phase 3 data. Pooled analysis of two multicenter, double-blind, placebo-controlled trials in HIV patients with excess abdominal fat, with safety extension data, supported the original approval and showed reductions in visceral adipose tissue with an acceptable safety profile over extended use . A more recent meta-analysis of randomized controlled trials in HIV-associated lipodystrophy pooled body composition, hepatic fat, and metabolic outcomes across the trial base ^[3]. This matters for the prescription question because it defines what a doctor is prescribing on-label versus off-label. A prescriber writing tesamorelin for a patient with diagnosed HIV lipodystrophy and documented visceral fat excess is on well-supported ground. A prescriber writing it for a 45-year-old wanting to "optimize body composition" is prescribing off-label, which is legal in the US but rests on a much thinner evidence base specific to that use.

Can a doctor legally prescribe tesamorelin off-label?

Yes. Off-label prescribing is legal in the United States as long as the prescriber has a legitimate medical reason and it's within the standard of care for their license. This is true for most FDA-approved drugs, more than tesamorelin. What off-label prescribing doesn't get you is FDA's endorsement that the drug works for that purpose. The trial evidence for tesamorelin is built almost entirely on HIV-associated lipodystrophy: visceral fat reduction , liver enzyme improvement tied to that visceral fat drop , effects on NAFLD in HIV , and even neurocognitive outcomes in HIV patients with abdominal obesity ^[4]. A 2024 study looked specifically at efficacy and safety in people with HIV who were also on integrase inhibitors, a modern antiretroviral context ^[5]. None of that trial base is about otherwise-healthy adults trying to lose visceral fat without HIV. A sports medicine and orthopaedics literature is starting to look at injectable peptide therapies, tesamorelin included, in athletic and musculoskeletal contexts, but these are described as reviews and primers on the drug class and safety landscape, not new efficacy trials proving benefit in that population ^[6][7][8]. If your prescriber cites those, ask what specifically they show, because "peptide therapies exist and have a safety profile worth knowing" is a different claim than "this peptide is proven for you."

What does a doctor check before writing a tesamorelin prescription?

A responsible tesamorelin prescription doesn't happen on the strength of a symptom checklist. At minimum, expect a clinical conversation about goals, a review of your health history, and bloodwork, because tesamorelin affects the GH/IGF-1 axis and glucose metabolism. In the original trials, safety and metabolic monitoring were baked into the protocol; the phase 3 program tracked glucose parameters and adverse events over extended treatment . Growth hormone secretagogues in general can raise IGF-1 and affect glucose handling, which is part of why growth hormone use in aging populations is discussed cautiously in the endocrine literature, with attention to metabolic risk and appropriate patient selection . Expect a prescriber to ask about, or test for, blood glucose or HbA1c, and possibly IGF-1 levels, before and during treatment. If a clinic will write a script with zero labs and zero follow-up, that's a signal about the quality of the practice, not about tesamorelin itself. For patients considering the mechanics of use once a prescription exists, see how to reconstitute tesamorelin and tesamorelin how to inject for the practical side.

Does insurance cover tesamorelin, and how does that affect getting a prescription?

Insurance coverage for Egrifta is tied to the approved indication. If you have HIV-associated lipodystrophy with documented excess abdominal fat, meeting criteria that typically involve waist circumference and imaging or exam findings, insurers are far more likely to cover it, though prior authorization is common and coverage varies by plan. Outside that diagnosis, coverage is rare to nonexistent. Off-label prescriptions for body composition goals in HIV-negative patients are almost always cash-pay, whether that's for brand-name Egrifta at full list price or a compounded version through a telehealth or specialty clinic route. Cost is a separate, large topic on its own; see tesamorelin cost for the actual numbers and how brand versus compounded pricing compares. The short version relevant here: the prescription requirement doesn't change based on how you're paying, but your options for who will write it often do.

What's the difference between getting Egrifta versus compounded tesamorelin prescribed?

Both require a prescription. The differences are in regulatory oversight, quality assurance, and typically cost. Egrifta and Egrifta SV are FDA-approved products, meaning the manufacturing, purity, and labeling went through FDA review ^[1][2]. Search the FDA's own drug product database, Drugs@FDA, and you'll find the approval record directly . Compounded tesamorelin comes from 503A pharmacies (compounding for individual patients under a prescription) or 503B outsourcing facilities (larger-scale compounding, still under a prescription, with somewhat more oversight than 503A) . Tesamorelin base is on FDA's list of bulk substances allowed for 503A compounding . Compounded product is not FDA-approved as a finished drug. That doesn't automatically mean it's unsafe, reputable compounding pharmacies operate under state board oversight and USP sterility standards, but it does mean there's no FDA review of that specific pharmacy's batch purity and potency the way there is for Egrifta. If a prescriber or clinic is vague about which one you're getting, ask directly. | Feature | Egrifta / Egrifta SV (brand) | Compounded tesamorelin |

Do I need to have HIV to get a tesamorelin prescription?

No, but you need a prescriber willing to write it off-label if you don't. HIV-associated lipodystrophy is the only FDA-approved indication ^[1][2], so a prescription for anyone outside that population is, by definition, off-label use. That's legal. Plenty of legitimate off-label prescribing happens across medicine. But it means the evidence a prescriber is relying on for you specifically is thinner than the phase 3 trial base built for the approved population, and it means insurance almost certainly won't help. Some clinics specializing in hormone optimization or peptide therapy will prescribe tesamorelin for visceral fat reduction or GH support in HIV-negative adults based on extrapolation from the HIV trial data plus general GH physiology. That's a reasonable clinical judgment call for some prescribers to make; it is not the same as tesamorelin being proven effective for that population in controlled trials.

What lab work or monitoring is typically required during treatment?

Once you have a prescription, ongoing monitoring is standard practice, not optional paperwork. The exact panel varies by prescriber, but commonly includes fasting glucose or HbA1c, IGF-1, and sometimes lipid panels, particularly early in treatment and periodically after. This tracks with the drug's mechanism: tesamorelin is a growth hormone-releasing hormone (GHRH) analogue, so it stimulates the body's own GH release rather than delivering exogenous GH directly ^[2]. That pulsatile stimulation still raises IGF-1 and can affect glucose metabolism, which is why the phase 3 program built metabolic monitoring into its protocol and why post hoc analyses have looked at subgroup differences, such as patients with versus without dorsocervical fat pads, in response and tolerability . If a clinic prescribes tesamorelin and never asks for follow-up labs at all, that's worth questioning regardless of whether the product is brand or compounded.

How long can you legally be prescribed tesamorelin, and does cycling matter?

There's no legal limit on prescription duration; that's a clinical decision between patient and prescriber, not a statutory one. In the HIV lipodystrophy trials, extension data followed patients on treatment well beyond the initial trial period, supporting longer-term use in that population under monitoring . Whether cycling on and off makes sense is a different, more practical question than a legal one, and it depends on your goals and how your body responds. See tesamorelin cycle length for that discussion in more depth. What is a legal consideration: a prescription is typically written for a defined refill period, and a prescriber needs an ongoing clinical reason (and often ongoing labs) to keep renewing it, especially for off-label use where there's no approved-label duration to point to.

Can telehealth clinics legally prescribe tesamorelin?

Yes, telehealth prescribing of tesamorelin is legal, subject to the same rules that govern any prescription: a licensed prescriber, a valid patient relationship, and a legitimate medical purpose. Many patients now get both on-label and off-label tesamorelin prescriptions through telehealth-based clinics rather than in-person visits. The practical questions to ask a telehealth provider are the same ones you'd ask any prescriber: do they order labs, do they explain whether you're getting brand Egrifta or a compounded version, and do they have a follow-up plan. A rushed intake form with no bloodwork requirement is a red flag regardless of delivery channel. Tesamorelin Co works with a provider-reviewed route that connects patients to licensed prescribers and names the fulfilling pharmacy partner directly, rather than operating as an anonymous drop-ship source. That distinction, knowing exactly who is prescribing and who is dispensing, is worth checking for with any provider you consider.

What happens if you buy tesamorelin without a prescription?

If you buy tesamorelin from a research-chemical seller with no prescription involved, you're outside the legal supply chain for human use, and you have no clinical oversight, no verified purity, and no dosing guidance tied to your actual labs or health status. This is also where most of the real safety risk in the tesamorelin conversation sits, not in the drug's approved mechanism, but in unregulated sourcing. Detection science for GHRH analogues has advanced specifically because of concern about non-medical, unsupervised use, particularly in sport ^[9]. That's a strong signal that unsupervised acquisition is common enough to warrant its own analytical detection literature, which is not a reassuring fact pattern for a would-be buyer. There is no scenario where skipping the prescription step is a good trade for saving time or money, given that the entire safety monitoring framework (glucose, IGF-1, injection site management) depends on having a prescriber attached to your use.

Who should not be prescribed tesamorelin?

Prescribers generally screen out or use extreme caution in patients with active malignancy (because GH-axis stimulation is a theoretical concern in cancer biology), pregnant or breastfeeding patients, and those with pituitary or hypothalamic disease that could interact with GHRH stimulation. These aren't unique to tesamorelin; they're standard cautions for GH-axis-active drugs. Patients with poorly controlled diabetes also warrant extra scrutiny, given tesamorelin's documented effects on glucose metabolism in trial populations . A careful prescriber will ask about all of this before writing anything, on-label or off. Dorsocervical fat pad status is one variable that's actually been studied directly: a post hoc analysis of the phase 3 trial data compared outcomes in patients with and without dorsocervical fat pads and found differences worth noting in response pattern. That's a good example of why individualized assessment matters more than a one-size prescription.

Frequently asked questions

Is tesamorelin a controlled substance?

No. Tesamorelin is a prescription drug but it is not a scheduled controlled substance under federal law. It requires a valid prescription from a licensed provider, same as many non-controlled prescription medications, but it doesn't carry the extra restrictions (like limited refills or DEA scheduling) that controlled substances do.

Can my primary care doctor prescribe tesamorelin?

Any licensed prescriber with prescribing authority can write for tesamorelin, including a primary care doctor, though many are unfamiliar with it since its approved use (HIV lipodystrophy) is a narrow specialty area. Off-label prescribing for other goals depends entirely on that individual doctor's comfort and clinical judgment.

Do I need to see a doctor in person to get tesamorelin?

Not necessarily. Telehealth prescribing is legal for tesamorelin as long as a valid patient-prescriber relationship and legitimate medical purpose exist. Many patients get prescriptions through telehealth clinics with video or phone visits plus lab work, rather than in-person appointments.

Is compounded tesamorelin legal to prescribe?

Yes. Tesamorelin is on FDA's list of bulk drug substances eligible for compounding under section 503A, and it also appears on the 503B outsourcing facility bulks list, meaning licensed pharmacies can legally compound it under a valid prescription, though it isn't FDA-approved as a finished product the way Egrifta is.

What tests do I need before getting a tesamorelin prescription?

Most responsible prescribers order baseline bloodwork, commonly fasting glucose or HbA1c and sometimes IGF-1, before starting tesamorelin, because it affects GH/IGF-1 signaling and glucose metabolism. Exact requirements vary by prescriber and by whether you're being treated on-label (HIV lipodystrophy) or off-label.

Will insurance pay for a tesamorelin prescription?

Only reliably if you have a documented HIV-associated lipodystrophy diagnosis with excess abdominal fat, which is the FDA-approved indication for Egrifta. Off-label prescriptions for other goals are almost always cash-pay, and prior authorization is common even for on-label use.

Can I get tesamorelin prescribed for weight loss if I don't have HIV?

A prescriber can legally write it off-label for that goal, but it is not FDA-approved for general weight loss, and the phase 3 trial evidence behind tesamorelin was generated specifically in HIV-associated lipodystrophy patients, not in a general obesity population.

How is Egrifta different from Egrifta SV?

Both are FDA-approved tesamorelin products for the same indication, HIV-associated lipodystrophy. Egrifta SV is a newer formulation with a simpler, lower-volume reconstitution process. Both require a prescription and are chemically the same active peptide, tesamorelin.

Can a prescription for tesamorelin be denied?

Yes. A prescriber can decline to prescribe tesamorelin for any patient where they judge the risk-benefit unfavorable, commonly in active cancer, uncontrolled diabetes, pregnancy, or pituitary disease. Telehealth clinics also sometimes decline based on intake screening if red flags come up in your history.

Do I need a prescription for tesamorelin bought from a research chemical website?

Legally, yes, tesamorelin for human use requires a prescription regardless of where you buy it. Research-chemical sellers who ship without one are operating outside that legal framework, and products from that channel carry no verified purity, dosing guidance, or clinical oversight.

How often do I need a new prescription or refill for tesamorelin?

There's no fixed legal duration; it depends on how your prescriber writes the script and structures follow-up. Off-label use typically requires more frequent reassessment since there's no approved-label duration to default to, while on-label HIV lipodystrophy treatment has extension trial data supporting longer-term supervised use.

Is tesamorelin legal to bring into the US from another country?

Bringing prescription drugs across US borders without a valid US prescription and proper documentation is generally not permitted, and tesamorelin is no exception. Importing it for personal use outside FDA-regulated channels carries legal and quality risk beyond just the prescription question.

Sources

1. PubMed, Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions: Peptide therapies, including GHRH analogues, are reviewed in orthopaedic contexts as an emerging but distinct evidence area from approved indications.
2. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians: Sports medicine literature frames injectable peptide therapies, tesamorelin included, as a class physicians need primer-level safety and use guidance on.
3. PubMed, Tesamorelin (2012): Tesamorelin is an FDA-approved growth hormone-releasing factor analogue indicated for excess abdominal fat in HIV-associated lipodystrophy.
4. PubMed, Tesamorelin, Nature Reviews Drug Discovery (2011): Tesamorelin is a GHRH analogue that stimulates endogenous growth hormone release, approved specifically for HIV-associated lipodystrophy.
5. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance: Reviews distinguish approved peptide therapies from unapproved ones used off-label in athletic performance contexts, relevant to tesamorelin's off-label use pattern.
6. PubMed, Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (2024): A 2024 study evaluated tesamorelin efficacy and safety specifically in people with HIV on modern integrase inhibitor regimens.
7. PubMed, Advances in the detection of growth hormone releasing hormone synthetic analogs (2021): Analytical detection methods for GHRH synthetic analogues like tesamorelin have advanced due to concerns about non-medical, unsupervised use.
8. PubMed, Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity (2025): Tesamorelin's neurocognitive effects have been studied specifically in HIV patients with abdominal obesity, not in a general population.
9. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: meta-analysis (2026): A meta-analysis of randomized controlled trials pooled body composition, hepatic fat, and metabolic safety outcomes of tesamorelin in HIV-associated lipodystrophy.
10. PubMed, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (2017): Tesamorelin-induced visceral fat reduction in HIV patients was associated with improved liver enzyme levels.
11. PubMed, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV (2019): A randomized, double-blind, multicenter trial evaluated tesamorelin's effects on NAFLD specifically in HIV patients.
12. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled phase 3 analysis (2010): Pooled phase 3 trial data with safety extension supported tesamorelin's approval, showing visceral fat reduction and monitored metabolic/glucose safety over extended use.
13. PubMed, Growth hormone in the aging male (2013): Growth hormone-axis therapies in aging populations require cautious patient selection due to metabolic risk considerations.
14. PubMed, Effect of tesamorelin in people with HIV with and without dorsocervical fat: post hoc analysis (2023): Post hoc analysis of phase 3 trial data found differences in tesamorelin response between patients with and without dorsocervical fat pads.
15. FDA, bulk drug substances used in compounding under section 503A: Tesamorelin is on FDA's list of bulk drug substances that may be used in compounding under section 503A.
16. eCFR, 21 CFR 216.23, the 503A Bulks List: 21 CFR 216.23 establishes the list of bulk drug substances, including those used for tesamorelin, eligible for 503A compounding.
17. eCFR, 21 CFR 216.24, the 503B Bulks List: 21 CFR 216.24 establishes the bulk drug substances list for 503B outsourcing facility compounding, under which tesamorelin can also be compounded.
18. Cornell Law School Legal Information Institute, 21 U.S.C. 353a, pharmacy compounding: Federal law under 21 U.S.C. 353a governs the conditions under which pharmacy compounding, including of tesamorelin, is permitted without full new drug approval.
19. FDA, Drugs@FDA drug product database: FDA's Drugs@FDA database contains the official approval record for Egrifta and Egrifta SV as approved drug products.